Previous 10 | Next 10 |
Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results PR Newswire LPCN 1144 was well tolerated over 72-week exposure with no observed safety signals Liver injury markers were reduced and maintained with extended LPCN 1144 treatment Obser...
Lipocine press release (NASDAQ:LPCN): Q1 GAAP EPS of -$0.04 misses by $0.02. As of March 31, 2022, the company had $42.0 million of unrestricted cash, cash equivalents and marketable investment securities compared to $46.6 million as of December 31, 2021. Shares +1.3% PM. For further d...
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022 PR Newswire SALT LAKE CITY , May 9, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products for neuroendo...
LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS PR Newswire Industry veterans Jill M. Jene , Ph.D. and Spyros Papapetropoulos M.D. Ph.D. appointed to Board SALT LAKE CITY , April 11, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a b...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Seanergy Maritime Holdings ( SHIP ): Dry bulk goods shipper with rising share price and growing fleet. Charah Solutions ( CHRA ): 50% upside in coal plant remediation stock. Lipocine ( LPCN ): Li...
Gainers: IGM Biosciences (IGMS) +105%. China SXT Pharmaceuticals (SXTC) +73%. Clever Leaves Holdings (CLVR) +42%. MicroVision (MVIS) +31%. LianBio (LIAN) +26%. TC Biopharm (TCBP) +26%. Robinhood Markets (HOOD) +25%. Kinnate Biopharma (KNTE) +24%. Auddia (AUUD) +23%. Molecular Templates (...
NeoGenomics (NEO) -29% on Q1 guidance cut; CEO to quit Progenity (PROG) -22% on Q4 earnings release. Stryve Foods (SNAX) -21% releases inaugural shareholder report. Kala Pharmaceuticals (KALA) -19% on Q4 earnings release. Lipocine (LPCN) -15% its partne...
LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO™ PR Newswire Commercial launch expected in 2Q 2022 SALT LAKE CITY , March 29, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company ...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Shares of Lipocine Inc. (NASDAQ:LPCN) traded today at $1.75, eclipsing its 52-week high. This new high was reached on approximately average trading volume as 767,000 shares traded hands, while the average 30-day volume is approximately 722,000 shares. Lipocine Inc. (NASDAQ:LPCN) defies a...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study PR Newswire Met standard bioequivalence (BE) criteria C max, AUC 0-t , and AUC 0- ∞ C trough criterion was met LPCN 1154 was well tolerat...
Shares of Lipocine Inc. (NASDAQ: LPCN) traded at a new 52-week high today and are currently trading at $8.96. So far today, approximately 78,318 shares have been exchanged, as compared to an average 30-day volume of 32,701 shares. Lipocine Inc., a clinical-stage biopharmaceutical company, foc...